Every Form 4 that Cullinan Oncology Inc (CGEM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CGEM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CGEM filings page.
Cullinan Therapeutics, Inc. (CGEM) reported that Chief Scientific Officer Jennifer Michaelson exercised stock options and sold shares on September 8, 2026. She exercised options to acquire 4,000 shares of common stock at an exercise price of $4.30 per share, leaving 78,987 shares underlying options outstanding. On the same date she sold 8,000 shares of common stock at a weighted average price of $21.57 per share in multiple trades between $21.31 and $21.83, under a Rule 10b5-1 trading plan adopted on August 7, 2025.
Cullinan Therapeutics Chief Scientific Officer Jennifer Michaelson exercised 30,000 stock options for Common Stock at an exercise price of $4.30 per share, then sold 30,000 Common Shares at a weighted average price of $20.26 per share pursuant to a Rule 10b5-1 trading plan adopted on August 7, 2025. The options exercised were from a grant that vested 25% on July 4, 2020, with the remainder vesting in 36 monthly installments, and she continues to hold 82,987 stock options of this series directly, expiring on October 28, 2030.
Cullinan Therapeutics Chief Scientific Officer Jennifer Michaelson reported an exercise-and-sell transaction in company stock. She sold 8,000 shares of common stock in an open-market sale at a weighted average price of $17.82 per share, executed under a pre-arranged Rule 10b5-1 trading plan established on August 7, 2025. On the same date, she exercised stock options for 4,000 shares of common stock at an exercise price of $4.30 per share. After these transactions, she directly owned 162,844 shares of Cullinan Therapeutics common stock and held 112,987 stock options exercisable at $4.30 per share, which expire on October 28, 2030.
Cullinan Therapeutics Chief Legal Officer Jacquelyn L. Sumer acquired 2,470 shares of common stock at $8.60 per share through the company’s 2021 Employee Stock Purchase Plan. The shares relate to the purchase period from January 1, 2026 through June 30, 2026 and were bought at 85% of the January 2, 2026 closing price. Following this routine ESPP transaction, she directly holds 130,559 shares of Cullinan Therapeutics common stock.
Cullinan Therapeutics Chief Financial Officer Mary Kay Fenton reported an acquisition of company stock through the 2021 Employee Stock Purchase Plan. She obtained 1,541 shares of common stock for the purchase period from January 1, 2026 through June 30, 2026.
The shares were bought at $8.60 per share, based on 85% of the closing price on January 2, 2026, as provided under the ESPP. Following this routine, compensation-related transaction, she directly holds 127,921 shares of Cullinan Therapeutics common stock.
Cullinan Therapeutics director Anthony Rosenberg received a grant of stock options covering 25,319 shares of Common Stock. The options have an exercise price of $13.55 per share and will vest in full on the earlier of June 16, 2027 or the company’s next annual meeting, contingent on his continued board service. Following this compensation grant, he holds options for 25,319 underlying shares directly, with no open-market buying or selling reported in this filing.
Cullinan Therapeutics director David D. Meek received a new stock option grant covering 25,319 shares of common stock. The option has an exercise price of $13.55 per share and represents a right to buy the company’s common stock directly.
According to the grant terms, the 25,319-share option will vest in full on the earlier of June 16, 2027 or the date of Cullinan Therapeutics’ next annual meeting, provided Meek continues to serve as a director through that vesting date. Following this grant, he holds stock options for 25,319 shares.
Cullinan Therapeutics director Stephen W. Webster received a stock option grant covering 25,319 shares of common stock. The option has an exercise price of $13.55 per share and was awarded as compensation, not an open-market purchase or sale. It vests in full on the earlier of June 16, 2027 or the company’s next annual meeting, contingent on his continued board service. Following this grant, Webster holds options for 25,319 underlying shares.
Cullinan Therapeutics director Andrew R. Allen received a grant of stock options covering 21,781 shares of common stock at an exercise price of $13.55 per share. These options vest in full on the earlier of June 16, 2027 or the company’s next annual meeting, subject to his continued board service.
Cullinan Therapeutics director Mary Thistle received a stock option grant covering 25,319 shares of common stock. The option has an exercise price of $13.55 per share and was granted at no cost to her.
The award vests in full on the earlier of June 16, 2027 or the company’s next annual meeting, as long as she continues serving as a director on that date. Following this grant, she holds options for 25,319 underlying shares.
Cullinan Therapeutics director Mittie Doyle received a new stock option grant. The award covers 21,781 shares of Common Stock at an exercise price of $13.55 per share. According to the terms, the option vests in full on the earlier of June 16, 2027 or the company’s next annual meeting, as long as she continues serving as a director.
Cullinan Therapeutics Chief Scientific Officer Jennifer Michaelson reported an exercise-and-sell transaction in company stock. She sold a total of 8,000 shares of Common Stock in open-market transactions at weighted average prices of $14.60 and $15.58, with actual trade prices ranging from $14.24 to $15.60. These sales were executed pursuant to a pre-established Rule 10b5-1 trading plan dated August 7, 2025. On the same day, she exercised stock options for 4,000 shares of Common Stock at an exercise price of $4.30 per share, converting a derivative position into additional common shares while using part of her holdings for liquidity.
Cullinan Therapeutics, Inc. Chief Scientific Officer Jennifer Michaelson reported option exercises and a share sale. On the same day, she exercised stock options for 4,000 shares of common stock at $4.30 per share through a derivative exercise, and then sold 8,000 common shares in the open market at a weighted average price of $15.68 per share, with individual trades ranging from $15.38 to $16.31. The sale was made under a pre-established Rule 10b5-1 trading plan dated August 7, 2025. Following these transactions, she directly held 170,844 shares of common stock and 120,987 shares underlying stock options.
Cullinan Therapeutics Chief Scientific Officer Jennifer Michaelson reported an open-market sale of 1,780 shares of common stock at a weighted average price of $14.14 per share. After this transaction, she directly holds 174,844 shares of Cullinan Therapeutics common stock.
The sale was effected under a pre-arranged trading plan established pursuant to Rule 10b5-1 on August 7, 2025. The reported price reflects a weighted average for multiple trades executed between $13.89 and $14.35 per share.
Cullinan Therapeutics, Inc. Chief Scientific Officer Jennifer Michaelson reported selling a total of 5,353 shares of common stock in open-market transactions. She sold 3,601 shares on February 24, 2026 at a weighted average price of $14.47 per share and 1,752 shares on February 23, 2026 at a weighted average price of $13.99 per share. These sales were effected under a Rule 10b5-1 trading plan and were described as covering personal income tax obligations upon vesting of restricted stock units. After the transactions, she directly holds 176,624 Cullinan Therapeutics common shares.
Cullinan Therapeutics reported that President and CEO Nadim Ahmed executed an open-market sale of 13,515 shares of common stock at $14.47 per share. According to the filing, the sale was made to cover personal income tax obligations upon vesting of restricted stock units. After this transaction, he directly owned 390,803 shares.
Cullinan Therapeutics Chief Medical Officer Jeffrey Alan Jones reported an open-market sale of 4,582 shares of common stock at $14.47 per share. According to the footnote, the sale was made to cover personal income tax obligations upon vesting of restricted stock units. After this transaction, Jones directly holds 159,968 shares of Cullinan Therapeutics common stock.
Cullinan Therapeutics, Inc. Chief Legal Officer Jacquelyn L. Sumer reported an open-market sale of 3,601 shares of common stock at $14.47 per share on February 24, 2026. According to the footnote, the sale was made to cover personal income tax obligations upon vesting of restricted stock units. After this transaction, she directly owned 128,089 shares.
Cullinan Therapeutics Chief Medical Officer trades shares to cover taxes. Jeffrey Alan Jones reported an open-market sale of 4,982 shares of common stock at $13.62 per share on February 20, 2026, to cover personal income tax obligations upon vesting of restricted stock units, and now holds 164,550 shares directly.
Cullinan Therapeutics, Inc. Chief Scientific Officer Jennifer Michaelson reported multiple equity transactions in company stock. On February 20, 2026, she exercised stock options for 8,000 shares of common stock at a stated exercise price of $4.30 per share, reflected through derivative and non-derivative entries. She then sold a total of 11,742 shares of common stock in open-market transactions at prices of $13.62 and $14.30 per share. A footnote states that a portion of the sales was made to cover personal income tax obligations upon vesting of restricted stock units and that the transactions were effected under a Rule 10b5-1 trading plan established on August 7, 2025. Following these transactions, her reported direct ownership remained in the range of approximately 180,000–190,000 shares of Cullinan Therapeutics common stock.
Cullinan Therapeutics Chief Legal Officer sells shares for taxes. Jacquelyn L. Sumer executed an open-market sale of 3,742 shares of Cullinan Therapeutics common stock at $13.62 per share on February 20, 2026 to cover personal income tax obligations upon vesting of restricted stock units. After this transaction, she directly holds 131,690 shares.
Cullinan Therapeutics, Inc. President and CEO Nadim Ahmed reported an open-market sale of common stock. On February 20, 2026, he sold 16,381 shares at an average price of $13.62 per share, according to the Form 4 filing.
A footnote explains the sale was made to cover personal income tax obligations arising from the vesting of restricted stock units. After this transaction, Ahmed still holds 404,318 shares of Cullinan Therapeutics common stock directly.
Cullinan Therapeutics Chief Financial Officer Mary Kay Fenton reported a tax-related share sale. On this Form 4, she sold 4,398 shares of common stock at $13.62 per share in an open-market transaction. According to the footnote, the sale was made to cover personal income tax obligations upon vesting of restricted stock units. After this transaction, she directly owned 126,380 shares of Cullinan Therapeutics common stock.
Cullinan Therapeutics, Inc. reported that Chief Legal Officer Jacquelyn L. Sumer received a grant of a stock option covering 230,000 shares of common stock. This option was reported as an acquisition of a derivative security.
According to the disclosure, the shares underlying the option vest over four years, with one forty-eighth of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Following this grant, Sumer was reported as directly holding options on 230,000 shares.
Jones Jeffrey Alan reported acquisition or exercise transactions in this Form 4 filing.
Cullinan Therapeutics reported that its Chief Medical Officer, Jeffrey Alan Jones, received a grant of stock options covering 300,000 shares of common stock on February 18, 2026. These options vest over four years, with one-forty-eighth of the grant vesting in equal monthly installments until the fourth anniversary of the grant date.
Cullinan Therapeutics reported that President and CEO Nadim Ahmed was granted a stock option covering 828,000 shares of common stock. The option was awarded at an exercise price of $0.00 per share, reflecting a compensatory grant rather than an open-market purchase.
According to the disclosure, the shares underlying the option vest over four years, with one forty-eighth of the option shares vesting in equal monthly installments until the fourth anniversary of the grant date. After this grant, the CEO held options covering 828,000 shares directly.
Cullinan Therapeutics, Inc. reported that Chief Business Officer Corrine Savill received a grant of stock options covering 175,000 shares of common stock. The options have an exercise price of $0.00 per share and vest over four years in equal monthly installments of one forty-eighth of the grant.
Cullinan Therapeutics, Inc. reported that its Chief Financial Officer, Mary Kay Fenton, acquired new equity awards. She received a stock option for 137,500 shares of common stock and a separate award covering 68,750 shares of common stock. The shares underlying the restricted stock unit award vest annually over four years. The shares underlying the option vest over four years, with one forty-eighth of the optioned shares vesting in equal monthly installments until the fourth anniversary of the grant date.
Cullinan Therapeutics, Inc. reported that its Chief Scientific Officer, Jennifer Michaelson, received new equity awards. She was granted stock options for 115,000 shares at an exercise price of $0.0000 per share and 57,500 shares of common stock as an equity award.
According to the disclosure, the 57,500 common shares are in the form of restricted stock units that vest annually over four years. The 115,000 stock options vest over four years as well, with one forty-eighth of the options vesting in equal monthly installments until the fourth anniversary of the grant date.
Cullinan Therapeutics Chief Scientific Officer Jennifer Michaelson reported an open-market sale of common stock. On February 12, 2026, she sold 416 shares of Cullinan Therapeutics, Inc. common stock at $12.03 per share.
According to the footnote, the sale was made to cover personal income tax obligations triggered by the vesting of restricted stock units. After this transaction, Michaelson directly beneficially owns 128,219 shares of Cullinan Therapeutics common stock.
Cullinan Therapeutics, Inc. insider trading report: Chief Scientific Officer Jennifer Michaelson reported a sale of company stock. On January 22, 2026, she sold 4,000 shares of Cullinan Therapeutics common stock at a price of $12.30 per share in an open-market transaction. The sale was carried out under a pre-established Rule 10b5-1 trading plan that was put in place on August 7, 2025, which is designed to allow insiders to sell shares according to a preset schedule. After this transaction, Michaelson directly beneficially owned 128,635 shares of Cullinan Therapeutics common stock.
Cullinan Therapeutics Chief Scientific Officer, a reporting officer of the company, disclosed small open-market stock sales in December 2025. On 12/12/2025, 2,148 shares of common stock were sold at $12.38 to cover personal income tax obligations related to vesting restricted stock units.
On 12/15/2025, 995 shares were sold at $11.90 under a pre-arranged trading plan established pursuant to Rule 10b5-1 on August 7, 2025. After these transactions, the officer beneficially owns 136,878 shares of common stock, including 2,017 shares purchased through the 2021 Employee Stock Purchase Plan for the purchase period from January 1, 2025 through June 30, 2025.
Cullinan Therapeutics, Inc. (CGEM) reported an insider transaction by its Chief Scientific Officer on a Form 4. On 11/24/2025, the officer sold 4,000 shares of common stock at $12.3 per share in an open-market sale. After this trade, the officer beneficially owns 138,004 shares of Cullinan common stock. The filing notes that this sale was carried out under a pre-established Rule 10b5-1 trading plan adopted on August 7, 2025, which is designed to allow insiders to sell shares according to a preset schedule.
Cullinan Therapeutics (CGEM): Reporting persons associated with Lynx1 Capital Management disclosed an open‑market purchase of 165,667 shares of common stock on 10/28/2025 at a weighted average price of $8.4005, executed across multiple trades ranging from $8.035 to $8.50.
Following the transaction, they report 8,963,500 shares beneficially owned on an indirect basis through Lynx1 Master Fund LP. The filing notes a standard disclaimer of beneficial ownership except to the extent of pecuniary interest.
Cullinan Therapeutics (CGEM): Lynx1-affiliated reporting persons disclosed open‑market purchases of Common Stock across four days, increasing their indirect holdings. Following the most recent transaction, beneficial ownership stood at 8,797,833 shares, held indirectly through Lynx1 Master Fund LP as described in the filing.
- 10/14/2025: 15,032 shares at a weighted avg price of $7.587 (purchases ranged $7.50–$7.68).
- 10/15/2025: 51,500 shares at $7.9427 (range $7.88–$8.00).
- 10/16/2025: 150,000 shares at $8.855 (range $8.68–$9.22).
- 10/17/2025: 32,217 shares at $7.8395 (range $7.78–$7.85).
The filing lists the transactions as purchases and notes the indirect ownership structure via Lynx1 Capital Management LP and related entities.
Lynx1 Capital Management LP and affiliated reporting person Weston Nichols disclosed purchases of Cullinan Therapeutics, Inc. (CGEM) common stock across three days. On 10/08/2025 they bought 556,300 shares at a weighted average price of $6.46, increasing indirect holdings to 7,645,743 shares. On 10/09/2025 they acquired 626,043 shares at a weighted average of $6.6958, bringing holdings to 8,271,786 shares. On 10/10/2025 they purchased 277,298 shares at a weighted average of $7.3617, raising indirect holdings to 8,549,084 shares. The shares are held directly by Lynx1 Master Fund LP, for which Lynx1 Capital Management LP serves as investment manager; the filing disclaims beneficial ownership except to the extent of any pecuniary interest.